ReFacto AF - summary of medicine characteristics

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

ReFacto AF 250 IU powder and solvent for solution for injection

Each vial contains nominally 250 IU* moroctocog alfa.

After reconstitution, each mL of solution contains approximately 62.5 IU moroctocog alfa.

ReFacto AF 500 IU powder and solvent for solution for injection

Each vial contains nominally 500 IU* moroctocog alfa.

After reconstitution, each mL of solution contains approximately 125 IU moroctocog alfa.

ReFacto AF 1000 IU powder and solvent for solution for injection

Each vial contains nominally 1000 IU* moroctocog alfa.

After reconstitution, each mL of solution contains approximately 250 IU moroctocog alfa.

ReFacto AF 2000 IU powder and solvent for solution for injection

Each vial contains nominally 2000 IU* moroctocog alfa.

After reconstitution, each mL of solution contains approximately 500 IU moroctocog alfa.

ReFacto AF 250 IU powder and solvent for solution for injection in pre-filled syringe

Each pre-filled syringe contains nominally 250 IU* moroctocog alfa.

After reconstitution, each mL of solution contains approximately 62.5 IU moroctocog alfa.

ReFacto AF 500 IU powder and solvent for solution for injection in pre-filled syringe

Each pre-filled syringe contains nominally 500 IU* moroctocog alfa.

After reconstitution, each mL of solution contains approximately 125 IU moroctocog alfa.

ReFacto AF 1000 IU powder and solvent for solution for injection in pre-filled syringe

Each pre-filled syringe contains nominally 1000 IU* moroctocog alfa.

After reconstitution, each mL of solution contains approximately 250 IU moroctocog alfa.

ReFacto AF 2000 IU powder and solvent for solution for injection in pre-filled syringe

Each pre-filled syringe contains nominally 2000 IU* moroctocog alfa.

After reconstitution, each mL of solution contains approximately 500 IU moroctocog alfa.

ReFacto AF 3000 IU powder and solvent for solution for injection in pre-filled syringe

Each pre-filled syringe contains nominally 3000 IU* moroctocog alfa.

After reconstitution, each mL of solution contains approximately 750 IU moroctocog alfa.

• * The potency (International Units) is determined using the European Pharmacopoeia chromogenic assay. The specific activity of ReFacto AF is 7,600–13,800 IU/mg protein. comparable to the 90 + 80 kDa form of factor VIII (i.e. B-domain deleted) and similar post-translational modifications to those of the plasma-derived molecule.

The manufacturing process for ReFacto was modified to eliminate any exogenous human- or animal-derived protein in the cell culture process, purification, or final formulation; and at the same time the invented name was changed to ReFacto AF.

After reconstitution, 1.27 mmol (29 mg) sodium per vial or pre-filled syringe.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU powder and solvent for solution for injection

Powder and solvent for solution for injection

White to off-white cake/powder

Clear, colourless solvent

ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU powder and solvent for solution for injection in pre-filled syringe

Powder and solvent for solution for injection in pre-filled syringe

White to off-white cake/powder in top chamber of the pre-filled syringe Clear, colourless solvent in bottom chamber of the pre-filled syringe

4. CLINICAL PARTICULARS4.1 Therapeutic indications

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

ReFacto AF is appropriate for use in adults and children of all ages, including newborns.

ReFacto AF does not contain von Willebrand factor, and hence is not indicated in von Willebrand’s di­sease.

4.2 Posology and method of administration

Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia A.

Treatment monitoring

During the course of treatment, appropriate determination of factor VIII levels is advised to guide the dose to be administered and the frequency of repeated infusions. Individual patients may vary in their response to factor VIII, demonstrating different half-lives and recoveries. Dose based on bodyweight may require adjustment in underweight or overweight patients. In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable.

When monitoring patients' factor VIII activity levels during treatment with ReFacto AF, use of the chromogenic assay is recommended. When using an in vitro thromboplastin time (aPTT)-based one-stage clotting assay for determining factor VIII activity in patients’ blood samples, plasma factor VIII activity results can be significantly affected by both the type of aPTT reagent and the reference standard used in the assay. Also there can be significant discrepancies between assay results obtained by aPTT-based one-stage clotting assay and the chromogenic assay. Typically, one-stage clotting assay results are 20–50% lower than the chromogenic substrate assay results. The ReFacto AF laboratory standard can be used to correct for this discrepancy (see section 5.2). This is of importance particularly when changing the laboratory and/or reagents used.

Posology

The dose and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of bleeding, and on the patient’s clinical condition. Doses administered should be titrated to the patient's clinical response. In the presence of an inhibitor, higher doses or appropriate specific treatment may be required.

The number of units of factor VIII administered is expressed in International Units (IUs), which are related to the current WHO standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in IU (relative to an International Standard for factor VIII in plasma). One IU of factor VIII activity is equivalent to the quantity of factor VIII in one mL of normal human plasma.

Another moroctocog alfa product approved for use outside Europe has a different manufacturing potency assigned that has been calibrated to the WHO International Standard using a one-stage clotting assay; this product is identified by the tradename XYNTHA. Due to the difference in methods used to assign product potency of XYNTHA and ReFacto AF, 1 IU of the XYNTHA product (one-stage assay calibrated) is approximately equivalent to 1.38 IU of the ReFacto AF product (chromogenic assay calibrated). If a patient normally treated with XYNTHA is prescribed ReFacto AF, the treating physician may consider adjustment of dosing recommendations based on factor VIII recovery values.

Based on their current regimen, individuals with haemophilia A should be advised to bring an adequate supply of factor VIII product for anticipated treatment when travelling. Patients should be advised to consult with their healthcare provider prior to travel.

On demand treatment

The calculation of the required dose of factor VIII is based upon the empirical finding that 1 IU of factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/dl. The required dose is determined using the following formula:

Required units (IU) = body weight (kg) x desired factor VIII rise (% or IU/dl) x 0.5 (IU/kg per IU/dl), where 0.5 IU/kg per IU/dl represents the reciprocal of the recovery generally observed following infusions of factor VIII.

The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case.

In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma levels (in % of normal or in IU/dl) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery:

Prophylaxis

For long-term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of factor VIII per kg body weight at intervals of 2 to 3 days. In some cases, especially in younger patients, shorter dose intervals or higher doses may be necessary.

The need for an increased dose relative to that used for adults and older children should be anticipated when treating younger children (less than 6 years of age) with ReFacto AF (see section 5.2)..

Elderly population

Clinical studies did not include subjects aged 65 and over. In general, dose selection for an elderly patient should be individualised.

Renal or hepatic impairment

Dose adjustment for patients with renal or hepatic impairment has not been studied in clinical trials.

Intravenous use.

ReFacto AF is administered by intravenous infusion over several minutes after reconstitution of the lyophilised powder for injection with sodium chloride 9 mg/mL (0.9%) solution for injection (provided). The rate of administration should be determined by the patient’s comfort level. Appropriate training is recommended for non-healthcare professionals administering the product.

For reconstitution instructions prior to administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known allergic reaction to hamster protein.

4.4 Special warnings and special precautions for use

Traceability

In order to improve traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Patients can affix one of the peel-off labels found on the vial or pre-filled syringe to document the batch number in their diary or for reporting any side effects.

Hypersensitivity

Allergic type hypersensitivity reactions have been observed with ReFacto AF. The medicinal product contains traces of hamster proteins. If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.

In case of shock, standard medical treatment for shock should be implemented.

Inhibitors

The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII pro-coagulant activity, which are quantified in Bethesda Units (BU) per mL of plasma using the modified assay. The risk of developing inhibitors is correlated to the severity of the disease as well as the exposure to factor VIII, this risk being highest within the first 50 exposure days but continues throughout life although the risk is uncommon.

The clinical relevance of inhibitor development will depend on the titre of the inhibitor, with low titre posing less of a risk of insufficient clinical response than high titre inhibitors.

In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests. If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.

Reports of lack of effect

Reports of lack of effect, mainly in prophylaxis patients, have been received in the clinical trials and in the post-marketing setting for ReFacto. The reported lack of effect with ReFacto has been described as bleeding into target joints, bleeding into new joints or a subjective feeling by the patient of new onset bleeding. When prescribing ReFacto AF it is important to individually titrate and monitor each patient's factor level in order to ensure an adequate therapeutic response (see section 4.8).

Cardiovascular events

In patients with existing cardiovascular risk factors, substitution therapy with factor VIII may increase the cardiovascular ris­k.

Catheter-related complications

If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered (see section 4.8).

Sodium content

After reconstitution this medicinal product contains 1.27 mmol (29 mg) sodium per vial or pre-filled syringe, equivalent to 1.5% of the WHO recommended maximum daily intake (RDI) of 2 g sodium for an adult. Depending on body weight of the patient and posology of ReFacto AF, patients could receive multiple vials or pre-filled syringes. This should be taken into consideration if the patient is on a low salt diet.

4.5 Interaction with other medicinal products and other forms of interaction

No interactions of recombinant coagulation factor VIII products with other medicinal products have been reported.

4.6 Fertility, pregnancy and lactation

Animal reproduction studies have not been conducted with factor VIII, therefore no data are available on fertility. Because of the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breast-feeding is not available. Therefore, factor VIII should be used during pregnancy and breast-feeding only if clearly indicated.

4.7 Effects on ability to drive and use machines

ReFacto AF has no influence on the ability to drive and use machines.

4.8 Undesirable effects

Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed infrequently for ReFacto, and may in some cases progress to severe anaphylaxis including shock (see section 4.4).

Trace amounts of hamster protein may be present in ReFacto AF. Very rarely, development of antibodies to hamster protein has been observed, but there were no clinical sequelae. In a study of ReFacto, twenty of 113 (18%) previously treated patients (PTPs) had an increase in anti-CHO antibody titre, without any apparent clinical effect.

Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with ReFacto AF. If such inhibitors occur, the condition may manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.

Tabulated list of adverse reactions

The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level). Frequencies have been evaluated according to the following convention: very common (> 1/10); common (> 1/100 to < 1/10) and uncommon (> 1/1,000 to < 1/100). The table lists adverse reactions reported in the clinical trials with ReFacto or ReFacto AF. The frequencies are based on all causality treatment emergent adverse events in pooled clinical trials with 765 subjects.

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

haemophilia A. PTPs = previously-treated patients, PUPs = previously-untreated patients

Paediatric population

One event of cyst in an 11-year old patient and one event described as confusion in a 13-year old patient have been reported as possibly related to ReFacto AF treatment

Safety of ReFacto AF was evaluated in studies that included both previously treated adults and previously treated children and adolescents (n=18, aged 12–16 years in a study and n=49, aged 7–16 years in a supporting study), with a tendency for higher frequencies of adverse reactions in children aged 7–16 years as compared to adults. Additional safety experience in children has been accrued through studies that encompassed both previously treated (n=18 aged <6 years and n=19 aged 6 to <12 years) and previously untreated (n=23 aged <6 years) patients and which supports a safety profile similar with that observed in adult patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

No symptoms of overdose have been reported with recombinant coagulation factor VIII products.

5. PHARMACOLOGICAL PROPERTIES5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antihaemorrhagics, blood coagulation factor VIII; ATC code: B02BD02.

ReFacto AF contains B-domain deleted recombinant coagulation factor VIII (moroctocog alfa). It is a glycoprotein with an approximate molecular mass of 170,000 Da consisting of 1438 amino acids.

ReFacto AF has functional characteristics comparable to those of endogenous factor VIII. Factor VIII activity is greatly reduced in patients with haemophilia A, and, therefore, replacement therapy is necessary.

When infused into a haemophiliac patient, factor VIII binds to the von Willebrand factor present in the patient’s cir­culation.

Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin, and a clot is formed. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy, the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

The data in the table below relates to PUP and PTP data from ReFacto AF studies in patients

<12 years.

Consumption and efficacy results in paediatric population

a The dose and frequency of ReFacto AF prescribed throughout the study were at the investigator’s dis­cretion as per local standard of care.

b Subjects in the PUP study were not required to follow a regular continuous prophylaxis treatment; however, with the exception of one subject (with only on demand (OD) treatment) the majority of subjects took regular prophylaxis infusions. Several began with OD infusions but switched to prophylaxis treatment during their participation, and some had only sporadic prophylaxis infusions.

c Subjects in the PTP study reported their FVIII treatment modality (prophylaxis or on demand) at baseline and were not required to maintain this modality as a condition of study participation. The dose and frequency of ReFacto AF prescribed throughout the study were at the investigator’s dis­cretion as per local standard of care.

Abbreviations: ABR= annualised bleeding rate

Immune Tolerance Induction

Data on immune tolerance induction (ITI) have been collected in patients with haemophilia A who had developed inhibitors to factor VIII. As part of the pivotal trial with ReFacto in PUPs, ITI data from 25 patients were reviewed (15 with high titres, 10 with low titres). Of these 25 patients, 20 had a decrease in inhibitor titres to < 0.6 BU/mL, of whom initially 11 of 15 had high titres (> 5 BU/mL) and 9 of 10 had low titres. Out of 6 patients who developed low titre inhibitors but did not receive ITI, 5 had similar titre decreases. No long-term outcome is available.

5.2 Pharmacokinetic properties

Pharmacokinetic properties of ReFacto, derived from a cross-over study of ReFacto and a plasma-derived FVIII concentrate, using the chromogenic substrate assay (see section 4.2), in 18 previously treated patients are listed in the table below.

Abbreviations: AUCt = area under the plasma concentration-time curve from zero to the last measurable

concentration; t>/2 = half-life; CL = clearance; FVIII:C = FVIII activity; MRT = mean residence time

In a study in which the potency of ReFacto AF, ReFacto and FVIII activity in patient plasma were measured using the chromogenic substrate assay, ReFacto AF was shown to be bioequivalent to ReFacto. The ratios of geometric least-square means of ReFacto AF-to-ReFacto were 100.6%, 99.5% and 98.1% for recovery, AUCt and AUC, (area under the plasma concentration curve from time zero to infinity), respectively. The corresponding 90% confidence intervals about the ratios of ReFacto AF to ReFacto geometric means were within the bioequivalence window of 80% to 125%, demonstrating bioequivalence of ReFacto AF to ReFacto.

In a cross-over pharmacokinetic study, the pharmacokinetic parameters for ReFacto AF were determined at baseline and followed up in 25 previously treated patients (> 12 years) after repeated administration of ReFacto AF for six months. The ratios of geometric least-square means of month 6-to-baseline pharmacokinetic were 107%, 100% and 104% for recovery, AUCt and AUC,, respectively. The corresponding 90% confidence intervals about the ratios of month 6-to-baseline for the above pharmacokinetic parameters were within the equivalence window of 80% to 125%. This indicates no time-dependent changes in the pharmacokinetic properties of ReFacto AF.

In the same study, in which the drug potency of ReFacto AF and a full-length recombinant factor VIII (FLrFVIII) comparator, and the FVIII activity measured in patient plasma samples were all determined using the same one-stage clotting assay at a central laboratory, ReFacto AF was shown to be pharmacokinetically equivalent to FLrFVIII in 30 previously treated patients (> 12 years) using the standard bioequivalence approach.

In PUPs, pharmacokinetic parameters of ReFacto were evaluated using the chromogenic assay. These patients (n=59; median age 10 ± 8.3 months) had a mean recovery at Week 0 of 1.5 ± 0.6 IU/dl per IU/kg (range 0.2 to 2.8 IU/dl per IU/kg) which was lower than that obtained in PTPs treated with ReFacto at Week 0 with a mean recovery of 2.4 ± 0.4 IU/dl per IU/kg (range 1.1 to 3.8 IU/dl per IU/kg). In the PUPs, the mean recovery was stable over time (5 visits during a 2-year period) and ranged from 1.5 to 1.8 IU/dl per IU/kg. Population pharmacokinetic modeling using data from 44 PUPs led to a mean estimated half-life of 8.0 ± 2.2 hours.

In a ReFacto AF study of 19 PUPs, the recovery at the beginning of the study in the 17 children aged 28 days to less than 2 years was 1.32 ± 0.65 IU/dl per IU/kg and in the 2 children aged 2 to <6 years were 1.7 and 1.8 IU/dl per IU/kg. Except in cases where inhibitors were detected, the mean recovery was stable over time (6 visits during a 2-year period) and individual values ranged from 0 (in presence of inhibitor) to 2.7 IU/dl per IU/kg.

In a study of 37 paediatric PTPs, the pharmacokinetic parameters of ReFacto AF observed after a 50 IU/kg dose are shown in the table below.

a Geometric mean (geometric CV%) for all, except for arithmetic mean ±SD for incremental recovery and t/2.

b Patients aged 6 to <12 years only.

Abbreviations: Cmax = maximum observed plasma concentration; CV= coefficient of variation; AUCinf = area under the plasma concentration-time profile from time zero extrapolated to infinite time; t/2 = terminal half-life; CL = clearance; Vss = steady-state volume of distribution.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and genotoxicity.

No investigations on carcinogenic potential or toxicity to reproduction have been conducted.

6. PHARMACEUTICAL PARTICULARS6.1 List of excipients

Sucrose

Calcium chloride dihydrate

L-Histidine

Polysorbate 80

Sodium chloride

Sodium chloride

Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products, including other infusion solutions.

Only the provided infusion set is to be used, because treatment failure can occur as a consequence of human-coagulation factor VIII adsorption to the internal surfaces of some infusion equipment.

6.3 Shelf life

3 years.

The product may be removed from refrigerated storage for one single period of maximum 3 months at room temperature (up to 25°C). At the end of this period of room temperature storage, the product must not be returned to refrigerated storage, but is to be used or discarded.

Chemical and physical in-use stability has been demonstrated for 3 hours at temperatures up to 25°C.

ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU powder and solvent for solution for injection

The product does not contain a preservative, and the reconstituted product should be used immediately, or within 3 hours after reconstitution. Other in-use storage times and conditions are the responsibility of the user.

ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU powder and solvent for solution for injection in pre-filled syringe

The product does not contain a preservative, and the reconstituted product should be used immediately, or within 3 hours after reconstitution or removal of the grey tip cap. Other in-use storage times and conditions are the responsibility of the user.

6.4 Special precautions for storage

ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU powder and solvent for solution for injection ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU powder and solvent for solution for injection in pre-filled syringe

Store and transport refrigerated (2°C – 8°C). Do not freeze.

Keep the product in the outer carton in order to protect from light.

For storage conditions of the reconstituted medicinal product, see section 6.3.

6.5 Nature and contents of container

ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU powder and solvent for solution for injection

250 IU, 500 IU, 1000 IU or 2000 IU powder in a 10 mL vial (type 1 glass) with a stopper (butyl) and a flip-off seal (aluminum) and 4 mL of solvent in a pre-filled syringe (type 1 glass) with a plunger stopper (butyl), a tip-cap (butyl) and a sterile vial adapter reconstitution device, a sterile infusion set, alcohol swabs, a plaster and a gauze pad.

ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU powder and solvent for solution for injection in pre-filled syringe

250 IU, 500 IU, 1000 IU, 2000 IU or 3000 IU lyophilised powder in top chamber and 4 mL of solvent in bottom chamber of the pre-filled syringe (type 1 glass) with butyl rubber plungers and closure, one plunger rod for assembly, a polypropylene vented sterile cap, a sterile infusion set, alcohol swabs, a plaster and a gauze pad.

Pack size of 1.

6.6 Special precautions for disposal and other handling

ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU powder and solvent for solution for injection

The vial of lyophilised product powder for injection must be reconstituted with the supplied solvent [sodium chloride 9 mg/mL (0.9%) solution] from the pre-filled syringe using the sterile vial adapter reconstitution device. The vial should be gently rotated until all of the powder is dissolved. Please see package leaflet, section 3, for additional information on reconstitution and administration.

After reconstitution, the solution is drawn back into the syringe. The solution will be clear or slightly opalescent and colourless. The solution is to be discarded if visible particulate matter or discolouration is observed.

ReFacto AF 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU powder and solvent for solution for injection in pre-filled syringe

The lyophilised powder in the top chamber of the pre-filled syringe must be reconstituted with the solvent [sodium chloride 9 mg/mL (0.9%) solution] in the bottom chamber of the pre-filled syringe. The pre-filled syringe should be gently rotated until all of the powder is dissolved. Please see package leaflet, section 3, for additional information on reconstitution and administration.

After reconstitution, the solution will be clear or slightly opalescent and colourless. The solution is to be discarded if visible particulate matter or discolouration is observed.

The product, when reconstituted, contains polysorbate-80, which is known to increase the rate of di-(2-ethylhexyl) phthalate (DEHP) extraction from polyvinyl chloride (PVC). This is to be considered during the preparation and administration of the product, including storage time elapsed in a PVC container following reconstitution. It is important that the recommendations in section 6.3 be followed closely.

Any unused product or waste material is to be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

1050 Bruxelles

Belgium

8. MARKETING AUTHORISATION NUMBER

EU/1/99/103/001

EU/1/99/103/002

EU/1/99/103/003

EU/1/99/103/004

EU/1/99/103/009

EU/1/99/103/006

EU/1/99/103/007

EU/1/99/103/008

EU/1/99/103/005

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 13 April 1999

Date of latest renewal: 15 April 2014